Minodronic Acid Hydrate Tablets 50mg (Bonoteo® / ボノテオ錠50mg)

JPY ¥4,700

Japanese Osteoporosis Treatment Agent (Minodronic Acid Hydrate 50mg). Oral tablet administered once every 4 weeks upon rising. 3 tablets (1 tablet x 3) per package. Mfd. by Astellas Pharma Inc., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥4,324
10 - 19 12% JPY ¥4,136
20 + 18% JPY ¥3,854
SKU: BON-50-TAB Category:

Description

Product Overview / 商品概要

Bonoteo Tablets 50mg (ボノテオ錠50mg)
Generic: Minodronic Acid Hydrate / ミノドロン酸水和物
Therapeutic Category: Osteoporosis Treatment Agent / 骨粗鬆症治療剤
Manufactured by: Astellas Pharma Inc. / アステラス製薬株式会社

Composition & Specification / 組成・規格

Active Ingredient: Minodronic Acid Hydrate 50mg per tablet / 1錠中 ミノドロン酸水和物 50mg
Additives: D-Mannitol, Croscarmellose Sodium, Hydroxypropylcellulose, Microcrystalline Cellulose, Magnesium Stearate, Hypromellose, Macrogol, Titanium Dioxide, Talc, Ferric Oxide / D-マンニトール、クロスカルメロースナトリウム、ヒドロキシプロピルセルロース、結晶セルロース、ステアリン酸マグネシウム、ヒプロメロース、マクロゴール、酸化チタン、タルク、三二酸化鉄
Appearance: Film-coated tablet, very light red, major axis approx. 13.1mm, minor axis approx. 7.0mm, thickness approx. 4.1mm, weight approx. 0.309g
外観: フィルムコーティング錠、ごくうすい赤色、長径 約13.1mm、短径 約7.0mm、厚さ 約4.1mm、重量 約0.309g

Indications / 効能効果

EN: Osteoporosis
JA: 骨粗鬆症

Dosage and Administration / 用法用量

EN: The usual adult dose is 50mg of minodronic acid hydrate administered orally once every 4 weeks upon rising, with a sufficient amount (approximately 180mL) of water or lukewarm water. After administration, the patient should not lie down for at least 30 minutes and should avoid eating, drinking (except water), and taking other oral medications.
JA: 通常、成人にはミノドロン酸水和物として50mgを4週に1回、起床時に十分量(約180mL)の水(又はぬるま湯)とともに経口投与する。なお、服用後少なくとも30分は横にならず、飲食(水を除く)並びに他の薬剤の経口摂取も避けること。

Contraindications / 禁忌

EN: Patients with disorders that delay esophageal transit such as esophageal stricture or achalasia; patients unable to remain upright for at least 30 minutes after administration; patients with a history of hypersensitivity to this drug or other bisphosphonate agents; patients with hypocalcemia; pregnant women or women who may be pregnant
JA: 食道狭窄又はアカラシア等の食道通過を遅延させる障害のある患者、服用時に上体を30分以上起こしていることのできない患者、本剤の成分あるいは他のビスホスホネート系薬剤に対し過敏症の既往歴のある患者、低カルシウム血症の患者、妊婦又は妊娠している可能性のある女性

Regulatory Information / 規制情報

Approval No.: 22300AMX00606
Sales Started: September 2011 / 2011年9月
Classification Code: 873999
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): PTP with patient package: 3 tablets (1 tablet x 3) / 患者さん用パッケージ付きPTP:3錠(1錠×3)
Other Available Packages (by special order): PTP with patient package: 3 tablets (1 tablet x 3)

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Minodronic Acid Hydrate Tablets 50mg (Bonoteo® / ボノテオ錠50mg)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Minodronic Acid Hydrate Tablets 50mg (Bonoteo®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.